Abstract
Due to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy in pancreatic adenocarcinoma and provides an update on current studies in the field.
Keywords: Pancreatic adenocarcinoma, chemoradiotherapy, review.
Current Pharmaceutical Design
Title:Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue
Volume: 20 Issue: 42
Author(s): Ludimila Cavalcante, David P. Kelsen and Kenneth H. Yu
Affiliation:
Keywords: Pancreatic adenocarcinoma, chemoradiotherapy, review.
Abstract: Due to its extremely high mortality rates, strong efforts continue to be made to develop new therapies in the treatment of pancreatic adenocarcinoma. The use of combined modality chemoradiotherapy for the treatment of pancreatic adenocarcinoma remains an approach with both promise and controversy. This article reviews the conflicting data with regards to role of combined modality therapy in pancreatic adenocarcinoma and provides an update on current studies in the field.
Export Options
About this article
Cite this article as:
Cavalcante Ludimila, Kelsen P. David and Yu H. Kenneth, Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue, Current Pharmaceutical Design 2014; 20 (42) . https://dx.doi.org/10.2174/1381612820666140826154724
DOI https://dx.doi.org/10.2174/1381612820666140826154724 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells as Delivery Vehicles for Oncolytic Adenoviral Virotherapy
Current Gene Therapy Pharmacogenomics of Cytochrome P450 Enzymes in Tumours
Current Pharmacogenomics PPARγ and Its Ligands: Potential Antitumor Agents in the Digestive System
Current Stem Cell Research & Therapy Cancer Stem Cells of Head and Neck Squamous Cell Carcinoma
Current Cancer Therapy Reviews Inflammation and Cancer: When NF-κB Amalgamates the Perilous Partnership
Current Cancer Drug Targets MEMS and Microfluidics for Diagnostics Devices
Current Pharmaceutical Biotechnology Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein and Aptamers
Current Topics in Medicinal Chemistry Carbon Nanotubes in the Treatment of Skin Cancers: Safety and Toxic ological Aspects
Pharmaceutical Nanotechnology Wnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Current Cancer Drug Targets Gene Expression Significance in Personalized Medicine of Non-small Cell Lung Cancer and Gene Expression Analyzing Platforms
Current Drug Metabolism Radiolabeling Methods and Nuclear Imaging Techniques in the Design of New Polymeric Carriers for Cancer Therapy
Current Applied Polymer Science Exploitation of the 3-Quinolinecarbonitrile Template for Src Tyrosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Gene Therapy in Plastic and Reconstructive Surgery
Current Gene Therapy Advances in Whole Genome Sequencing Technology
Current Pharmaceutical Biotechnology Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Protein & Peptide Letters Elastin-Like Recombinamers As Smart Drug Delivery Systems
Current Drug Targets The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Micro-CT Assessments of Potential Anti-Osteoporotic Agents
Current Drug Targets Blocking the PI3K/PKB Pathway in Tumor Cells
Current Medicinal Chemistry - Anti-Cancer Agents The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine